靶向细胞代谢:CPI-613使胰腺癌细胞对放射治疗增敏
本研究探讨线粒体代谢抑制剂CPI-613(devimistat)能否改变胰腺导管腺癌细胞能量代谢并增敏放疗。体外实验显示,单次2 Gy和10 Gy放疗联合CPI-613较单纯放疗显著抑制MiaPaCa-2和Panc-1细胞生长,并增强细胞死亡。CPI-613联合吉西他滨或5-氟尿嘧啶在2 Gy放疗存在下协同抑制MiaPaCa-2细胞增殖。
要点
- CPI-613联合单次2 Gy和10 Gy放疗较单纯放疗显著抑制胰腺癌细胞生长
- CPI-613联合放疗增强胰腺癌细胞死亡,并改变关键线粒体代谢物
- CPI-613联合吉西他滨或5-氟尿嘧啶在2 Gy放疗存在下协同抑制细胞增殖
核心结论
- 结果支持CPI-613联合放疗这一新组合值得进一步开展临床前和早期临床研究。
- 一项旨在确定CPI-613联合放化疗治疗胰腺导管腺癌患者最大耐受剂量的1期试验已启动(NCT05325281)。
研究设计与样本
- 体外研究,使用胰腺导管腺癌细胞系MiaPaCa-2和Panc-1。
- 采用台盼蓝拒染法、集落形成实验和7-氨基放线菌素D实验分别检测细胞活力、克隆潜力和细胞死亡。
- 使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐和球体形成实验在MiaPaCa-2细胞中测定CPI-613联合放疗与化疗药物(吉西他滨或5-氟尿嘧啶)的协同效应。
- 通过液相色谱-质谱联用对接受放疗、CPI-613或两者联合处理的细胞进行代谢物谱分析以确定能量代谢变化。
主要发现
- 单次2 Gy和10 Gy放疗联合CPI-613较单纯放疗显著抑制胰腺导管腺癌细胞生长。
- 分子分析显示在蛋白水平抑制α-酮戊二酸脱氢酶。
- 放疗联合CPI-613处理增强胰腺导管腺细胞死亡。
- CPI-613联合放疗后靶向代谢组学分析显示关键线粒体代谢物改变,联合处理靶点覆盖更广。
- CPI-613联合吉西他滨或5-氟尿嘧啶在2 Gy放疗存在下协同抑制MiaPaCa-2细胞增殖。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Local tumor progression is a cause of significant morbidity and mortality in patients with pancreatic ductal adenocarcinoma (PDAC) with surgically unresectable disease. Novel and effective approaches to accomplish durable local control are urgently needed. We tested whether CPI-613 (devimistat), a first-in-class investigational small molecule inhibitor of mitochondrial metabolism, was capable of altering cancer cell energy metabolism and sensitizing PDAC cells to radiation therapy (RT). METHODS AND MATERIALS: The effect of a combined treatment of RT with CPI-613 on the viability of, clonogenic potential of, and cell death induction in PDAC cells (MiaPaCa-2 and Panc-1) was determined using a trypan blue dye exclusion assay, a colony formation assay, and a 7-amino-actinomycin D assay, respectively. The synergistic effects of CPI-613-RT and chemotherapeutic agents (gemcitabine or 5-fluorouracil) were measured in MiaPaCa-2 cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and spheroid formation assay. Changes in energy metabolism were determined by profiling metabolites treated with either RT, CPI-613, or both using liquid chromatography-mass spectrometry. RESULTS: This study demonstrates that a combination of single-fraction RT (2 and 10 Gy) with CPI-613 significantly inhibits PDAC cell growth compared with RT alone. Molecular analysis revealed inhibition of α-ketoglutarate dehydrogenase at the protein level. In addition, we demonstrate enhanced cell death of PDAC cells when treated with RT-CPI-613 combination. Targeted metabolomic analysis on PDAC cells post-CPI-613-RT treatment revealed alterations in key mitochondrial metabolites, with broader target engagement by the combination treatment, indicating the sensitization of CPI-613-treated PDAC cells to RT. Furthermore, a combination treatment of CPI-613 with either gemcitabine or 5-fluorouracil in the presence of 2 Gy RT synergistically inhibits PDAC cell proliferation. CONCLUSIONS: Our results support a novel combination of CPI-613-RT that warrants further preclinical and early-phase clinical investigations. A phase 1 trial designed to identify the maximum tolerated dose of CPI-613 in combination with chemo-RT in patients with PDAC was recently initiated (NCT05325281).
引用
- Khan HY, Kamgar M, Aboukameel A, et al. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Adv Radiat Oncol. 2022. PMID: 36479231. doi:10.1016/j.adro.2022.101122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。